IL-17 has also been found to promote pancreatic ductal adenocarcinoma progression and immune checkpoint blockade therapy resistance by triggering NET formation, while IL-17 blockade enhances immune checkpoint blockade sensitivity (55). The gene discussed is IL17A; the disease is pancreatic ductal adenocarcinoma.